Statins equivalent for CVD prevention


Clinical Question:

Are there any differences in outcomes among the major statins?

Bottom Line:

The overall effectiveness of statin therapy on the most important outcomes — decreasing mortality, heart attacks, and strokes — is not different among the 3 major statins. These are the results from a meta-analysis; no study has directly compared equivalent doses of 2 statins. (LOE = 1a)

Reference:

Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006;151:273-81.

Study Design:

Meta-analysis (randomized controlled trials)

Funding:

Self-funded or unfunded

Setting:

Outpatient (any)

Synopsis:

The researchers conducted this analysis of the research on the benefit of statins in the prevention of cardiovascular disease (CVD). The statins under consideration were pravastatin (Pravachol), simvastatin (Zocor), and atorvastatin (Lipitor). They authors identified, through a search of MEDLINE and the Cochrane Controlled Trials Register databases, all randomized controlled trials of at least 1000 participants that evaluated CVD or mortality as an outcome over the course of at least 1 year. The used only English language studies. They took other short cuts in the systematic review process that likely had little effect on their conclusions; they did not perform duplicate searching or data abstraction. They identified 8 studies enrolling almost 64,000 people that compared 1 of the statins with either placebo or usual care. The authors did not include the single study that directly compared 2 statins since the marketing-friendly goal of that study was to compare the intensity of treatment rather than the relative effectiveness of the 2 drugs. All studies showed a similar degree of reduction in lipid levels. There was no difference among the statins in reducing fatal coronary heart disease, nonfatal myocardial infarctions, fatal and nonfatal strokes, all cardiovascular deaths, or mortality due to any cause.

This entry was posted in efectividad clinica, enfermedad cardiovascular, estatinas, factor de riesgo cardiovascular, Medicamentos, POEM. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s